Nhps Contract: Fill & Download for Free

For me all 3 decision are very good. Modi Govt Fared On The Economy. It's Time For An Audit. Let’s do it.The economy is a mysterious com­pound, though. A lot of it is based on perception, experience and memory. People judge on the basis of tangible factors like remembered pain, or felt comfort. Has the Modi experience matched the promised Modi magic of 2014? Verifiably not. But has its patchwork quilt offered enough warmth to see it through 2019? We will know in a few months. The farmer will also vote, but not necessarily only as farmer. There are also things beyond the economy, stupid.What Has Worked For ModiRoads and highways Taken off after hiccupsDigitisation Move towards digital payments picking upTax net Widened by 15-20 per cent post GST and DeMoGST Helped to ease business and ­improve tax administrationHealth Insurance Higher health insurance through Ayushman BharatWhat Has Proved DismalDemonetisation Failed to achieve any goals, hit GDPMSMEs Hit by DeMo and GSTEmployment Job creation remains a question markMake In India Yet to make an impactFarmers In crisis, with no real gainsEffects are not always presented to us in manifest form. Sometimes they have to be inferred from what’s not there. A universal sense of well-being—what was called the ‘feelgood’ factor in 2004—is now not as perceptually salient among the middle class or other strata as it was then. What else is missing or present? And why this exercise? Because a new economic epoch for India was the central claim the Narendra Modi campaign had made in 2014—the presumed economic miracle of the ‘Gujarat model’ was to be extended all over. Fifty-four months later, it’s a good time to assess the results since the Modi regime’s pure policy phase is mostly done, and any big policy rollouts hereafter will likely be election-flavoured. So how does it stack up?The last day of November, though, these saw spanking new highways inundated, ironically, with the other narrative. It was a significant day for India’s farmers. About 10,000 of them had congregated in the national capital to talk about what the Modi government had left unfulfilled in the past four-and-a-half years. Even in their ang­uish, they built a bridge—apologising to the city-dwellers for causing them inconvenience, and listing the astonishing difference between what the farmer makes and how much a Delhiite pays. The angst resonated also because the aam janata in cities, hit by ­ever-spiralling fuel prices and straitening home budgets, is taking a critical look at NaMonomics too.CRISIL chief economist Dharma Kirti Joshi agrees farmers have reason to be upset as their price realisations have dipped despite higher MSPs ann­ounced by the government. “Unf­ortunately, it’s a trade-off—we need to improve productivity, that’s the route to sustainability, but when output inc­reases, prices fall and you have a bon­anza of low inflation,” he says. It’s a vicious cycle, marked by little long-term vision, that has been on for years. Earlier regimes are as culpable (rem­ember the suicide statistics from the UPA era). It’s the further deficiency of short-term support that’s exacerbating the situation, despite the Modi government’s crop insurance scheme.Beyond the lack of attention to agriculture too, there’s more critique than cheer about the government’s performance on the economic front from exp­erts and economists across the board. They see a canvas largely of blanks, with some bright spots where the government has excelled and shown work on the ground. With less than six months left of its tenure, one could naturally expect some vote-garnering strategies—creation of employment conclaves, perhaps loan waivers. But experts do feel that, despite the measures it took to boost the economy, the Modi regime’s performance has not been stellar as compared to the UPA. They agree things could have been pulled down much further—the government managed to hold it and prevent a real slowdown—but we are much below the optimal rate of growth, by a few percentage points.Things are on an improving track in some sectors. According to ICRA, a broad-based improvement is visible in October 2018, comparing year-on-year (YoY) growth performance, in as many as 14 of the 16 early economic indicators. This largely reflects the adjustment of production schedules related to the later start of the festive season, as well as factors such as base effects and the receding impact of floods in parts of the country. Accordingly, industrial growth is likely to display a healthy pickup in October 2018, from the level recorded in September 2018.But the general feeling among exp­erts is that broad objectives kept changing over the years—no objective was really achieved as such. The oft-repeated joke is that DeMo was for climate change. This is, of course, one initiative that polarised opinions sharply—eulogised or thoroughly dismantled, often by the same economist (follow the Arvind Subramaniam trail here). Partly because the phenomenon, which came almost like a tsunami, a classic Black Swan event, had a complex effect too. Says economist Y.K. Alagh, chancellor of the Central University of Gujarat, “It was done in a clumsy way, but what it did was inc­rease the tax revenue base once and for all. But it did not at all decrease the process of creating black money as it has started again in great earnest.” The latest data shows a growth of 15-20 per cent in I-T returns. India’s tax-to-GDP ratio has also increased from 5.5 per cent to 5.8 per cent.Prof N.R. Bhanumurthy of the National Institute of Public Finance and Policy too is critical. He says DeMo’s objectives were never fixed. “The government kept changing the goalposts. The positive outcome is rel­ated to the tax base, which has inc­reased significantly both in terms of direct and indirect tax, visible in the buoyancy of economy. But this is not entirely due to demonetisation. It should be looked at together with GST,” he adds. Many economists feel the message never went through. Says Ishwar Hegde, economist and founder-MD of Sun Fan Energy, “It was supposed to bring back currency. However, the narrative went wrong for the government. I agree it was badly planned and badly executed. We could have done much better.”Some experts believe the lack of focus on the social sector was because of attention being on other areas. Says Barua, “In every government, something gets priority and others do not. A lot of social sector issues are governance issues, but much more could have been done. The need to pay more attention to this side emerged in the middle of the NDA’s term. Also, the social sector is difficult to figure out because of Centre-state issues and it’s not clear who is res­ponsible for the sluggishness.”Infrastructure is possibly the only area where the government has achieved a lot on the ground, especially in roads and highways, even ports. Says Barua, “The only cure for the balancesheet is for the government to invest actively. The government did it by investing in roads and infrastructure. There has been a coh­erent macro-economic strategy post the slowdown of 2012 and one can see the elements of a plan.”elmed by the proactive Nitin Gadkari, highways have seen a lot of visible expansion. Data released by the Union ministry of road transport and highways indicates the Modi government built 73 per cent more highways in its first four years as compared to the last four years of UPA-II. According to reports, 28,531 km national highways were constructed since FY 2014-15, contrasting with 16,505 km by the previous government up to FY 2013-14, a clear gain of an astounding 12,026 km.On a macro level, though, the ­economic highway ahead may not be very smooth: a tough fiscal ride is ­predicted. Says ICRA principal economist Aditi Nayar, “Fears of a fiscal slippage may intensify following the sharp 23.5 per cent YoY rise in the fiscal deficit in April-October FY2019, which has crossed the budget estimate for the full year, despite the rel­ief offered by the recent correction in crude oil prices.” The extent of a pot­ential fiscal slippage in FY2019, Nayar says, would be shaped by factors like targets being met for GST, excise duty, dividends/profits and disinvestment, and the adequacy of outlays for rev­ised MSPs, the NHPS or Modicare, fuel and other subsidies.Tax revenue growth continues to display mixed trends, with a healthy expansion in direct taxes juxtaposed with a contraction in indirect tax collections. The uptick in headline GST collections in October 2018 is likely to have been led by quarter-end ­adjustments. It remains to be seen whether GST collections continue to exceed Rs 1 trillion in the remainder of FY2019, particularly in the festive months, despite the recent GST rate cuts. Nayar expects a shortfall in indirect tax revenues in FY2019 relative to the budgeted level, driven by CGST and excise collections.Reference: Modinomics: How Has Modi Govt Fared On The Economy? It's Time For An AuditPlease do Upvote & Share if you like !!!Also Follow me for more such answers.

A biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced results from in vitro neutralization studies of sera from individuals vaccinated with Moderna COVID-19 Vaccine showing activity against emerging strains of SARS-CoV-2.The study showed no significant impact on neutralizing titers against the B.1.1.7 variant relative to prior variants. A six-fold reduction in neutralizing titers was observed with the B.1.351 variant relative to prior variants. Despite this reduction, neutralizing titer levels with B.1.351 remain above levels that are expected to be protective.The two-dose regimen of the Moderna COVID-19 Vaccine at the 100 µg dose is expected to be protective against emerging strains detected to date.Nonetheless, Moderna today announced its clinical strategy to proactively address the pandemic as the virus continues to evolve. First, the Company will test an additional booster dose of its COVID-19 Vaccine (mRNA-1273) to study the ability to further increase neutralizing titers against emerging strains beyond the existing primary vaccination series. Second, the Company is advancing an emerging variant booster candidate (mRNA-1273.351) against the B.1.351 variant first identified in the Republic of South Africa. The Company is advancing mRNA-1273.351 into preclinical studies and a Phase 1 study in the U.S. to evaluate the immunological benefit of boosting with strain-specific spike proteins.Moderna expects that its mRNA-based booster vaccine (whether mRNA-1273 or mRNA-1273.351) will be able to further boost neutralizing titers in combination with all of the leading vaccine candidates.The in vitro study assessed the ability of mRNA-1273 to elicit potently neutralizing antibodies against the new SARS-CoV-2 variants, using sera from eight Phase 1 clinical trial participants (aged 18-55 years) who received two 100 µg doses of mRNA-1273, and separately using sera from non-human primates (NHPs) immunized with two doses of 30 µg or 100 µg of mRNA-1273.For the B.1.1.7 variant, neutralizing antibody titers remained high and were generally consistent with neutralizing titers relative to prior variants. No significant impact on neutralization was observed from either the full set of mutations found in the B.1.1.7 variant or from specific key mutations of concern. Although these mutations have been reported to lessen neutralization from convalescent sera and to increase infectivity, sera from the Phase 1 participants and NHPs immunized with mRNA-1273 were able to neutralize the B.1.1.7 variant to the same level as prior variants.For the B.1.351 variant, vaccination with the Moderna COVID-19 Vaccine produces neutralizing antibody titers that remain above the neutralizing titers that were shown to protect NHPs against wildtype viral challenge. While the Company expects these levels of neutralizing antibodies to be protective, pseudovirus neutralizing antibody titers were approximately 6-fold lower relative to prior variants. These lower titers may suggest a potential risk of earlier waning of immunity to the new B.1.351 strains.Important biomedical notes:The Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) is supporting the continued research and development of the Moderna COVID-19 Vaccine with $955 million in federal funding under contract no. 75A50120C00034. BARDA is reimbursing Moderna for 100 percent of the allowable costs incurred by the Company for conducting the program described in the BARDA contract. The U.S. government has agreed to purchase supply of the Moderna COVID-19 Vaccine under U.S. Department of Defense contract no. W911QY-20-C-0100.Moderna has also received authorization for its COVID-19 vaccine from regulatory authorities in the United States, Canada, Israel, the European Union, the United Kingdom and Switzerland. Additional authorizations are currently under review in other countries and by the World Health Organization. A summary of the Company’s work to date on COVID-19 can be found here.AUTHORIZED USE IN THE UNITED STATES:The Moderna COVID-19 Vaccine has been authorized for emergency use by the U.S. Food and Drug Administration (FDA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.IMPORTANT SAFETY INFORMATIONDo not administer the Moderna COVID-19 Vaccine to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine.Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the Moderna COVID-19 Vaccine. Monitor Moderna COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/).Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished response to the Moderna COVID-19 Vaccine.The Moderna COVID-19 Vaccine may not protect all vaccine recipients.Adverse reactions reported in a clinical trial following administration of the Moderna COVID-19 Vaccine include pain at the injection site, fatigue, headache, myalgia, arthralgia, chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site, and erythema at the injection site.Available data on Moderna COVID-19 Vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. Data are not available to assess the effects of Moderna COVID-19 Vaccine on the breastfed infant or on milk production/excretion.There are no data available on the interchangeability of the Moderna COVID-19 Vaccine with other COVID-19 vaccines to complete the vaccination series. Individuals who have received one dose of Moderna COVID-19 Vaccine should receive a second dose of Moderna COVID-19 Vaccine to complete the vaccination series.Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Moderna COVID-19 Vaccine.Vaccination providers must complete and submit reports to VAERS online at https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to VAERS, call 1-800-822-7967. The reports should include the words " Moderna COVID- 19 Vaccine EUA " in the description section of the report.Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 24 development programs are underway across these therapeutic areas, with 13 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

First of all, this is a very biased question. Last 5 years are one of most peaceful years we have in the last 3 decades. Fewer riots, almost no big terrorist attack in India, we have lost fewer soldiers compared to the last 15 years, we have fewer districts which falls into the red corridor. I won't go all the way to explain each and every scheme started by Modi government but I will try to cover only a few important ones which I think has brought significant changes.In 2014 only 38% population had access to toilets but now almost 95% population got access to toilets. That’s how you improve the life of your citizens. You start from the very bottom.In 2014 only 51% adult population of India had bank accounts but now almost 87% of adults bank accounts. Bank accounts are very important in the age of technology. Families are getting all the benefits directly into their bank accounts. The Guinness Book of World Records recognized this achievement, stating: "The most bank accounts opened in one week as a part of the financial inclusion campaign is 18,096,130 and was achieved by the Government of India from August 23 to 29, 2014". A sizable 41% of account owners in India are already using their accounts to make or receive digital payments. This is a remarkable feat achieved in just 5 years.More than 6 crore families have got free LPG connections because of Ujjwalla scheme. The World Health Organisation hailed PMUY as decisive intervention by the government to facilitate the switch to clean household energy use.Corruption is at an all-time low. Maybe that’s why you think there is mayhem. The Narendra Modi government have scored well on this point. There has been no serious corruption charge against the ministers of the government. Scams in the allocation of government contracts have not been reported in the last four years. E-auctioning has been implementedOur ranking in Ease of doing business has improved. India has improved its rank by 53 positions in the last two years and 65 positions in the last four years. Currently, we are ranked at 77th position.The National Health Protection scheme is a major initiative by Modi government. NHPS offers healthcare covers up to Rs 5 Lakh per family for serious illnesses. This scheme aims to cover 10 crore families or 50 crore peoples of economically weaker section of our society.18,374 villages had received electricity under the DDUGJY; out of which 14,582 villages were in eastern India. Of these, 5,790 villages were in India’s North Eastern region. Elephanta Island, off the Mumbai coast, despite it being a tourist attraction and a UNESCO world heritage site, three villages on the island didn’t have electricity access even after 70 years of independence. Now they got access to electricity. This is development. But we are still away from 100% household’s electrification but govt is working hard to achieve this in the coming year.Inflation used to be in double digits during last government but Modi government has been successful in controlling it.We are in a far better position now compared to 2014. Railway stations are cleaner. There are fewer rail accidents and deaths compared to last few years. Sports in India is flourishing. GST, demonetization, Khelo India, Make in India, Mudra and many more.On the basis of these improvements, Modi is going to ask for votes in 2019. 5 years is not sufficient enough in a country as huge as India. He truly deserves another term and I am sure he will get it. #NamoAgainThank you.